US PTAB Patent Cases
8,722 decisions indexed
Page 150 of 291 · 8,722 total
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s 11,674,517 LVAD patent, asserting that all 19 challenged claims are obvious over four prior‑art references. The petition argues that the prior art discloses every claim limitation and that discretionary denial is unwarranted.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories has filed an IPR petition seeking cancellation of Miracor Medical’s 357 Patent covering a magnetically levitated LVAD. The petition relies on four prior‑art references to argue that all challenged claims are obvious under 35 U.S.C. §103.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Tesla, Inc. v.Intellectual Ventures II
Tesla, Inc. successfully convinced the PTAB that its claims against Intellectual Ventures II LLC were likely unpatentable based on prior art references Matsushima and Yu/Miyazaki. The Board granted institution, moving the dispute toward trial over key terms like 'integration time' in dynamic range camera technology.
Tesla, Inc. v.Intellectual Ventures II
The PTAB granted institution for Tesla against Intellectual Ventures II regarding patent 9706500. The review will examine claims related to transmit power control in wireless networks.
Tesla, Inc. v.Intellectual Ventures II
The PTAB granted institution for Tesla against Intellectual Ventures II regarding patent 10952153. The review challenges the obviousness of TPC commands in wireless networks.
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
Micron Technology initiated an IPR against Yangtze Memory Technologies regarding NAND Flash memory claims, challenging the patent on grounds of anticipation and obviousness. The Board found a reasonable likelihood of unpatentability for several key claims over prior art (Dong), leading to the institution of the proceeding.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories successfully petitioned the PTAB to challenge 19 claims of MIRACOR MEDICAL SA's LVAD patent based on obviousness (35 U.S.C. § 103). The Board found sufficient evidence for institution, adopting broader claim constructions for key terms like 'magneto coupling.'
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories successfully petitioned to challenge claims of MIRACOR MEDICAL SA's VAD patent based on obviousness (35 U.S.C. § 103). The PTAB granted institution, finding a reasonable likelihood of prevailing over multiple prior art references.
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
Abbott Laboratories successfully petitioned to challenge MIRACOR MEDICAL SA's cardiac assist pump patent based on obviousness (35 U.S.C. § 103). The PTAB institution decision found sufficient evidence of unpatentability over the Bourque/Wampler combination, despite arguments regarding specific claim limitations and prior art scope.
PHISON ELECTRONICS CORPORATION v.Vervain, LLC
Phison’s post‑grant review petition includes this exhibit of supporting evidence for its challenge to Vervain’s U.S. Patent 8,891,298.
PHISON ELECTRONICS CORPORATION v.Vervain, LLC
The PTAB denied Phison Electronics’ post‑grant review petition against Vervain’s 11,830,546 patent covering a mixed‑level NAND flash storage system. The Board found Phison’s evidence insufficient to meet the “more likely than not” standard for any of the asserted grounds. No institution was ordered.
Sinclair Pharma Limited et al. v.HydraFacial LLC
HydraFacial seeks Director Review after the PTAB instituted a copycat IPR despite a parallel ITC case. The patent owner contends the Board failed to apply Fintiv factors, warranting a discretionary denial under § 314(a).
Sinclair Pharma Limited et al. v.HydraFacial LLC
The Board initiated a sua sponte Director Review of an IPR concerning HydraFacial's facial treatment device patent after the ITC found the claims valid and commercially successful. The proceeding is stayed pending the Director's opinion.
Sinclair Pharma Limited et al. v.HydraFacial LLC
The USPTO denied Sinclair Pharma’s request for Director Review of the institution decision in IPR2025-00145 concerning HydraFacial’s patent 11,865,287. The institution of the IPR remains in place.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Court decision.
Sinclair Pharma Limited et al. v.HydraFacial LLC
The PTAB denied Sinclair Pharma’s request for a rehearing of the order that vacated the institution of IPR2025‑00145 concerning HydraFacial’s skin‑care device patent. The Board found no basis to grant rehearing after reviewing the parties’ submissions.
Sinclair Pharma Limited et al. v.HydraFacial LLC
HydraFacial has filed a Director Review request in IPR2025‑00145, restricting the petitioner to a brief, evidence‑free response.
Amazon.com, Inc. et al. v.NL Giken Inc.
Amazon and its affiliates settled the IPR against NL Giken, leading the PTAB to terminate the proceeding.
Amazon.com, Inc. et al. v.NL Giken Inc.
Amazon and its affiliates jointly moved to terminate the IPR over U.S. Patent 10,880,592 after reaching a confidential settlement with NL Giken.
PHISON ELECTRONICS CORPORATION v.Vervain, LLC
Phison Electronics has petitioned the PTAB for inter‑partes review of Vervain’s 8,891,298 patent covering a hybrid NAND flash memory system. The petition asserts that all 11 claims are obvious under 35 U.S.C. § 103 in view of multiple prior‑art references. The Board must decide whether to institute the proceeding.
Tesla, Inc. v.Intellectual Ventures II
Tesla has filed an IPR petition seeking cancellation of all eight claims of Intellectual Ventures II’s ’889 patent covering closed‑loop power control in CDMA/3G networks. The challenger argues the claims are obvious over the Dateki patent, the Mate publication, and the Chitrapu publication, which disclose the same F‑DPCH mechanisms before the patent’s priority date.
Tesla, Inc. v.Intellectual Ventures II
Tesla has filed an IPR petition seeking cancellation of 18 claims of IV’s ’670 LTE‑MTC patent, arguing they are obvious over Wallen and Berggren. The petition argues that the prior art was not considered during prosecution and that discretionary denial is unwarranted.
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
Micron has filed an IPR petition challenging Yangtze Memory’s 3D NAND ‘666 patent, asserting that claims 17, 19, and 20 are obvious over multiple prior‑art references. The petition seeks institution and cancellation of the claims.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Sinclair Pharma has filed an IPR petition challenging HydraFacial's skin‑treatment patent (US 11,865,287). The petition alleges obviousness over four prior‑art references and requests cancellation of 41 claims. The Board has not yet ruled on institution.
Amazon.com, Inc. et al. v.NL Giken Inc.
Amazon has filed an IPR petition seeking cancellation of all 13 claims of NL Giken’s ’592 patent, arguing obviousness over Walker and Chang references and opposing discretionary denial.
Tesla, Inc. v.Intellectual Ventures II
Tesla challenged Intellectual Ventures II's wireless communication patents under obviousness (103). The PTAB decided to institute the IPR on all eight claims after finding a reasonable likelihood of success.
Tesla, Inc. v.Intellectual Ventures II
Tesla successfully petitioned to challenge Intellectual Ventures II's '670 Patent under Section 103, leading the PTAB to grant institution. The Board found reasonable likelihood of unpatentability based on prior art references Wallen and Berggren regarding LTE/MTC communication systems.
PHISON ELECTRONICS CORPORATION v.Vervain, LLC
The PTAB denied Phison Electronics Corporation's request to institute IPR against Vervain, LLC's patent 8,891,298. The denial was based on the Fintiv factors, primarily due to significant overlap with ongoing parallel district court litigation.
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
Micron Technology successfully petitioned the PTAB to challenge a key claim in Yangtze Memory Technologies' patent. The Board granted institution based on obviousness over prior art references like Kim and Nam, advancing the dispute into an active IPR phase.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.